Advanced Cancer Clinical Trials in Durham, North Carolina

4 studies are recruiting for advanced cancer in Durham, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    PHN-012-001 Site, Durham, North Carolina
    Locations
    26 in total
    Run by
    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

  2. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke Cancer Institute, Durham, North Carolina
    Locations
    2 in total
    Run by
    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

  3. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Duke Cancer Center/ DUMC, Durham, North Carolina
    Locations
    18 in total
    Run by
    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

  4. A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

    This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Duke University - Trent Center, Durham, North Carolina
    Locations
    28 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06174987 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.